Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients

Autor Queiroz-Telles, Flávio de Google Scholar
Silva, Nanci Google Scholar
Carvalho, Miriam M. Google Scholar
Alcântara, Ana Paula Google Scholar
Matta, Daniel Archimedes da Autor UNIFESP Google Scholar
Barberino, Maria G. Google Scholar
Bartczak, Sergio Google Scholar
Colombo, Arnaldo Lopes Autor UNIFESP Google Scholar
Instituição Federal University of Paraná Clinical Hospital
Aliança Hospital
Universidade Federal de São Paulo (UNIFESP)
Janssen-Cilag Farmacêutica do Brasil
Resumo This study was a non-comparative multicenter clinical trial to evaluate the efficacy and tolerability of itraconazole oral solution 200 mg/day (100 mg twice a day in the fasting state) for the treatment of oropharyngeal candidiasis in AIDS patients. We included 50 patients who were treated and followed for up to 3 weeks after ending therapy in the analysis. Mycological cures at the end of therapy occurred in 20/50 patients (40%), but colonization by Candida sp. was recorded in 42/50 (84%) by the end of follow-up. A high rate of clinical response was observed in 46/50 (92%), and the response was sustained for up to 21 days after stopping therapy in 24/46 patients (52%). Clinical relapses were documented among 22 patients, but all causative fungal organisms associated with a relapse were susceptible to itraconazole. There were many patients with persistence or recurrence of Candida, but without mucositis. Relapse of Candida mucositis was significantly related to low levels of CD4 lymphocytes exhibited by symptomatic patients. The drug was well tolerated by all but 1 patient. We conclude that itraconazole oral solution (100 mg bid for 7-14 days) is a well tolerated and effective treatment for suppressing the symptoms of oropharyngeal candidiasis in AIDS patients. Patients with severe immunosuppression may relapse and require frequent cycles of treatment or longterm suppressive therapy.
Palavra-chave AIDS
candidiasis
itraconazole
Idioma Inglês
Data de publicação 2001-04-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 5, n. 2, p. 60-66, 2001.
ISSN 1413-8670 (Sherpa/Romeo)
Publicador Brazilian Society of Infectious Diseases
Extensão 60-66
Fonte http://dx.doi.org/10.1590/S1413-86702001000200003
Direito de acesso Acesso aberto Open Access
Tipo Artigo
SciELO S1413-86702001000200003 (estatísticas na SciELO)
Endereço permanente http://repositorio.unifesp.br/handle/11600/1151

Exibir registro completo




Arquivo

Nome: S1413-86702001000200003.pdf
Tamanho: 33.50KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta